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ABSTRACT
The research described in this review briefly
summarizes evidence that short term
pharmacological enhancement of noradrenergic
(NA) synaptic activity, combined with symptom
relevant experience (SRE), promotes functional
recovery of some symptoms of cortical damage
in rat, cat and human beings even when
treatment is initiated from days to weeks after
injury. A summary is provided of the numerous
drugs tested in rodent cortical injury models
which have been proven useful for predicting
beneficial or harmful effects on behavioral
outcome in human stroke. The pattern of drug
effects indicates a central role for NA in
functional recovery. Additionally, studies of the
effects of direct intraventricular infusion of
monoamine neurotransmitters are reviewed and
further support the hypothesized role of NA in
recovery from some symptoms of cortical injury.
The site of NA/SRE interaction to promote
recovery from hemiplegia apparently involves
the cerebellar hemisphere contralateral to the
cortical injury. Microinfusions of NA into the
contra- but not ipsilaterai cerebellar hemisphere
dramatically enhance recovery. Furthermore,
like its systemic action, microinfusion of the c1-
NA receptor antagonist, phenoxybenzamine,
reinstates hemiplegia. A "permanent" symptom
of motor cortex injury in the cat is the complete
loss of tactile placing contralateral to the injury
which does not spontaneously recover for as
long as seven years after ablation. This posturai
reflex is temporarily restored for 8-12 hours
following amphetamine administration.
However, this permanently lost reflex can be
enduringly restored by transplanting
catecholamine secreting adrenal tissue into the
wound cavity. The experiment is reviewed in
detail and involves chromaffin cell autografts
into the frontal cortex ablation wound cavity
producing a restoration of tactile placing for the
7-10 month duration of the study. This enduring
restoration of tactile placing is considered a
result of the release of catecholamines into the
CNS from the grafted chromaffin cells found, by
histochemical methods, surviving 7-10 months
after transplant. Lastly, we attribute these
delayed treatment effects to an attenuation of a
diaschisis, or remote functional depression, in
morphologically intact areas anatomically
connected to the area of injury. The widespread
reduction of glycolytic and oxidative
metabolism, produced by focal cortical injury, is
normalized by the same treatment which
alleviates symptoms and is worsened by drugs
which exacerbate deficits. These data support
the hypothesis that providing SRE during a
period of enhanced NA synaptic activity
produces an enduring functional recovery after
cortical injury by attenuating remote functional
depression. This treatment for enhancing
recovery is especially attractive since it is
effective even when begun weeks after cortical
damage.
KEY WORDS
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INTRODUCTION
Brain damage resulting from stroke or traumatic
brain injury (TBI) produces signifieam, and too
often permanent,, impairment of physical, and/or
cognitive abilities in approximately 800,000
individuals in the U.S. alone each year /39,58/.
There are approximately 300,000 reported cases of
first stroke/54/, and while most patients show some
recovery, stroke accounts for almost half the
hospitalizations for neurological disability/41/and
is the cause of more than 10% of all deaths/66/.
Some consider TBI to be a more devastating brain
injury than stroke because it primarily affects a
younger population, requiring a more prolonged
period of expensive medical care and loss of
productive years. The incidence of major head
injury for the 17-44 age group in this country rose
from 351,000 in 1972-73 to 609,000 in 1974-75
/14/. Of the more than 300,000 permanently
disabled Americans each year due to trauma,
neurological deficits account for most of the deficits
/65/.
The true cost of severe TBI is incalculable. The
medical and rehabilitation efforts to help TBI cases
are prolonged, labor intensive and astronomically
expensive. The direct hospitalization costs for
severe head trauma cases have been calculated at
two trauma centers in Maryland at $105,350 per
case for one year. When the authors extrapolated
the data to the 16-45 year age group for patients for
one year and only in the state of Maryland for 1983
the cost was estimated at 29 million dollars/48/.
Clearly, brain damage, a serious, survivable injury,
is a major medical problem and has no
acknowledged treatment/24,25/.
The dominant theme of current research on
therapy for brain damage has focused on very early
interventions to limit the spread of "secondary"
injury, such as attenuating excitotoxicity, initiated
by the initial insult/1,57/. These important research
efforts are likely to result in increased survival of
brain injured individuals, some perhaps with
lessened deficits if treatment is initiated in the first
hours after a stroke or TBI. Such patients will still
have persisting disabilities and unfortunately many
will be reached too late for these potential injury-
limiting therapies to be effective. The research
presented in this review describes an experimental
therapeutic regimen that can be initiated relatively
long after cortical injury has occurred. An
accelerated rate of recovery to higher functional
levels can be achieved after a short treatment period
beginning 1 day after injury in the rat and 10 days
after injury in the cat.
AMPHETAMINE PLUS EXPERIENCE PROMOTES
FUNCTIONAL RECOVERY
To our knowledge, the first observation that D-
amphetamine (AMPH) could enhance function lost
after brain injury, albeit transiently, was reported by
Maling and Acheson in 1946 /49/. They reported
that AMPH administration restored fighting, hind
limb stepping, tactile and proprioceptive placing
reflexes for up to 9 hours in low decerebrate cats.
There have been some follow-up laboratory
investigations. These studies confirmed the original
observations on postural reflexes using animals with
different lesions or using related drugs. Our
laboratory and others have reported that AMPH
also ameliorates the cortical injury-induced
symptoms involving more complex behaviors,
ranging from locomotion to visually guided
behavior, to learning and memory /2,6,18,21-
23,28,33,37,38,40,42,50,53,62,64/. (However, this
effect on learning and memory has not been
systematically studied.) Neglect of the intriguing
early observations that amphetamine could enhance
functional recovery after brain injury may be
attributable to several factors: 1) The drug effects
were on postural reflexes, behaviors seemingly
remote from clinical problems; 2) The restoration of
reflexes was "drug dependent", only lasting during
the period of drug action; 3) The Zeitgeist that brain
injury was only manageable and not amenable to
treatment.
Interest in a potential pharmacotherapy for brain
injury began in the 1980s based on two
developments. First, a wide acceptance of the
"excitotoxicity" concept, which suggested the
usefulness of pharmacological treatment within the
first hours after brain injury /1,57/. Second,
accumulating literature which indicated enhanced
functional recovery by short-term administration of
AMPH combined with SRE even when initiated
days or weeks following brain injury (for reviews
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see/19,24,25/). This latter development, which is
the focus of this review, originated with the 1982
Feeney et al. /21/ report that a single administration
of AMPH (2.0 mg/kg i.p., a low dose in rat,
producing few sterotypies or piloerection and only
mild anorexia for about 6 hours) administered 24
hours after unilateral ablation of the sensorimotor
cortex (SMCX) combined with SRE in rats
produced an enduring accelerated recovery from
hemiplegia measured by beam-walking (BW) agility.
This ablation model has been suggested to be an
animal model for functional recovery after stroke
/35/.
Subsequently, Hovda and Feeney /37/ described
a similar enhancement of recovery from hemiplegia
measured by BW in the hemiplegic cat when AMPH
treatment was not initiated until 10 days after
unilateral frontal cortex ablation. Of great
significance was the fact that the enhanced recovery
was not simply a transient pharmacological effect
but endured long after any direct drug effect had
dissipated. Treated cats were fully recovered on the
BW test by 21 days after injury and maintained the
recovery from hemiplegia, whereas control animals
had not recovered in 60 days when the experiment
was terminated. This treatment effect was even
more dramatic in cats with large bilateral frontal
ablations /62/. These severely disabled animals
required three treatments spaced at four day
intervals to achieve recovery whereas the control
group showed little improvement.
In a rat model of stroke/55/homologous blood
clots were used as emboli. These emboli occlude the
end arterioles of the middle cerebral artery causing
seizures, death (40% mortality), weight loss and a
very severe and enduring locomotor disability.
These marked deficits were not improved by a
single administration of AMPH but required
multiple AMPH administrations or a short-term,
very low dose continuous infusion of AMPH (by
osmotic minipump, s.c., 1 mg/kg/day) for 7 days to
enhance recovery. This dose of AMPH infusion
produced no anorexia in normal rats and,
paradoxically, treated stroke rats lost less body
weight than saline controls and had fully recovered
locomotor agility while the control animals had
severe locomotor disabilities 30 days post infarct.
In studies of TBI, the severity of disability has
been shown to be an important factor in determining
effects on recovery from hemiplegia/4/. In a rat
focal impact trauma model to produce SMCX TBI
/20/, AMPH/SRE was found to enhance BW
recovery/25/. Traumatic cortical injury apparently
requires a slightly higher dosage to promote
recovery, as has been reported for stroke models
/38,55/. The hemisphere injured also appears to
alter the dose response curve/43/.
Moreover, the AMPH/SRE effects on functional
recovery are likely to be different in males and
females. Female cats have been studied in every
ablation study from this laboratory using that
species. But the number of cats has been too small
to indicate subtle gender differences such as
requiring different dosages. As only male rats have
been studied in the ablation and trauma models,
dearly females must also be investigated; because of
their short estrous cycle, four days, this would have
to be monitored to clearly interpret gender
differences in effects on outcome measures.
The most important factor modifying the effect
ofAMPH on functional recovery is the experience
the animal receives during the period of apparent
drug action. In the hemiplegic rat and cat SRE (e.g.
BW trials) must be provided during the period of
drug action for any facilitation of locomotor
recovery. If the rats are confined to a small cage to
prevent major ballistic movements, AMPH alone
given at 24 hours post SMCX ablation produces no
facilitation of recovery from hemiplegia/21/. In an
experiment using hemiplegic cats two groups were
given the same AMPH dose and the same number
of BW trials. One group received the SRE
immediately prior to and the other group alter a
single AMPH administration; only the latter group
had a facilitated locomotor recovery/37/.
In the motor system one cannot truly control the
animals’ experience. One can only allow or prod the
animal into making the desired movements.
However, in experiments on vision, the
experimenter has complete control over SRE, since
turning off the lights prevents any visual experience.
This was utilized to carefully study the generality of
the necessity of SRE during the time of AMPH
action for promoting functional recovery after
cortical injury. The experiment was conducted
studying binocular depth perception, measured by
visual cliff performance, a "function" which is
permanently and completely lost after bilateral
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ablation of cortical areas 17, especially its mesial
face, and 18 in the cat /23/. This profound and
"permanent" deficit can be enduringly restored after
four doses of AMPH, but only if the animals are
kept in the light after amphetamine administration,
i.e. given SRE during the period of drug action.
Even after seven doses of AMPH there is no
recovery if the animals are housed in darkness for
eight hours after each drug administration.
In addition to indicating the necessity of SRE
during the first hours after AMPH administration,
these findings have four other important
implications: 1) The AMPH/SRE therapy for brain
injury can be utilized to treat qualitatively different
deficits after injury to different cortical areas. The
AMPH/SRE promotes recovery of binocular depth
perception and hemiplegia following unilateral
frontal cortex or posterior cortical injuries
respectively. 2) The AMPH/SRE is effective in
enhancing recovery after bilateral /23,62/ or
unilateral injury. This indicates that the
mechanism(s) mediating this recovery does not
involve the contralateral homologous cortex. As the
locus coeruleus and cerebellum have been
hypothesized /19,24-26/ to mediate hemiplegia
recovery, histochemical studies implicate the
superior colliculus to be additionally involved in
recovery ofbinocular depth perception (See/19/for
a discussion and description of a confirmation
experiment). Histochemical measurements of
oxidative metabolism implicate alleviation of
depressed collicular activity as a basis for this
remarkable recovery/19/. 3) This experiment most
clearly indicates that AMPH/SRE therapy does
much more for brain injury than just accelerate
recovery. The loss of depth perception after
bilateral visual cortex ablation, if untreated, would
never recover. 4) For short-term AMPH/SRE to be
effective alter bilateral visual cortex ablation,
treatment can be initiated 10 days after brain injury
but treatment started later than the 3rd month after
injury was ineffective/23/. Importantly, this therapy
appears to have a long therapeutic time window.
Amphetamine administration combined with
SRE does not enhance performance on all sensory-
motor tasks atter SMCX injury. For example, after
SMCX TBI the recovery of fine motor
coordination, measured by forepaw grasping ability,
is not significantly altered, even by multiple
treatments, even though BW recovery is enhanced
in the same animals /24,25/. Moreover, AMPH
retards BW recovery after cerebellar lesions /9/.
Clearly, the indications and contraindications of
AMPH/SRE should be delineated.
EVALUATION OF OTHER DRUGS
We hypothesized that increased NA activity is
involved in the effects of AMPH/SRE oh recovery
after cortical injury. However, AMPH has effects
on many neurotransmitter systems in addition to
NA. In the normal rat, AMPH dramatically
increases the release of NA /3,5,30,45-47,52,56/,
dopamine (DA) /3,15,30,51, 56/, gamma-
aminobutyric acid/5,15/, acetylcholine/5,15/, and
serotonin/3,15,30,59/. However, many studies have
been conducted in this laboratory and in others to
determine which one or more of the
neurotransmitters released by AMPH is critical for
the AMPH/SRE facilitation of recovery after
cortical injury. For example, using the same
paradigm, a single dose of the AMPH analogues,
and catecholamine agonists, phentermine and
phenylpropanolamine/24,25/, given 24 hours after
SMCX ablation in rat, both produce e.nduring BW
recovery. However, a single dose of methyl-
phenidate, a stimulant which blocks catecholamine
reuptake, unlike AMPH which primarily produces
transmitter release, did not facilitate BW recovery
using our standard BW rat regimen. However, in
further studies a significant and enduring
enhancement of BW agility was produced by a
single dose of methylphenidate when the number of
BW trials was increased early aiter drug
administration/42/. This drug presumably required
more early BW experience because of its shorter
half-life compared to AMPH. It is now clear that
these pharmacological effects of NA/SRE on
functional recovery are not attributable to the
stimulant properties of these drugs but to the
increased NA activity they produce. Specifically, it
has recently been shown that the antidepressant
desiprimine, which lacks stimulant properties but
does block NA reuptake, also facilitates recovery
from hemiplegia in the rat ablation model/11/.
A pharmacological strategy to analyze the
neurotransmitter system(s) involved in the
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AMPH/SRE effect is to administer specific receptor
agonists and antagonists using the same model and
test paradigm that clearly demonstrated the AMPH
and related drug effects on BW recovery/19,24,25,
29,60,61/. The data from these studies using
ablation are summarized in Table 1. The results
using the same test after TBI are summarized in
Table 2. All experiments listed used our
conservative test to assess drug effects on BW
recovery. At 24 hours after SMCX ablation rats
were given a single dose of the test drug and BW
recovery evaluated for several days to several
weeks depending upon the laboratory conducting
the experiment. We consider this to be a
conservative screening test since any effects on BW
recovery are only evaluated following a single dose
administered 24 hours after SMCX injury. The
experiments involving cats all used large frontal
cortex ablations to produce hemiplegia or bilateral
visual cortex ablations to produce depth perception
deficits and treatment was initiated 10 days after
surgery. In the cat, three AMPH/SRE treatments at
4-day intervals were conducted.
The data summarized in Tables 1 and 2 indicate
TABLE 1
Drugs tested for effects on recovery of function after cortical ablations
Catecholamine agonists
D-Amphetamine (rat:/18,21.,33/; cat:/22,23,62/)
Monoamine agonist
0.5 or mg/kg, no significant (NS) effects;
2 and 4 mg/kg, significant facilitation motor and vision
Methylphenidate/42/
Catecholamine agonist
10 mg/kg, significant facilitation with multiple or
repeated doses
Phenylpropanolamine/25/
Catecholamine agonist
10 mg/kg, NS effects;
15 and 20 mg/kg, significant facilitation
Phentermine/25/
Catecholamine agonist
6 or 24 mg/kg, NS effects;
12 mg/kg, significant facilitation
Catecholamine antagonists
Haloperidol/24,25,29,60/
Catecholamine antagonist
0.4 mg/kg, blocks AMPH facilitation, retards
spontaneous recovery
Reuptake blockers
Desipramine/11/
Inhibits NA reuptake
6 and 19 mg/kg, significant facilitation
Trazodone/11/
Inhibits 5-HT reuptake
6 and 12.5 mg/kg, significant facilitation
Specific receptor agonists
Phenylephrine/61/
NA1 receptor agonist
2,4, or 8 mg/kg, NS effects
Prazosin/61/
NA1 receptor antagonist
2 or 4 mg/kg, NS effects
Clonidine/34/
NA2 receptor agonist
0.02, 0.06, and 0.2 mg/kg, significant retardation of
recovery (However see/60/, NS effects)
Yohimbine/61/
NA2 receptor antagonist
0.5 or 5 mg/kg, NS effects;
10 mg/kg, significant facilitation
Idazoxan/24,25,35/
NA o2 receptor antagonist
1.0 mg/kg, NS effects;
2.0 mg/kg, significant facilitation
Apomorphine/22/
Dopamine receptor agonist
0.5 mg/kg transient, weak restoration of tactile placing in
cat;
0.2 to 20 mg/kg, NS effects in rat (unpublished data)
Methoxamine (unpublished data)
NA1 receptor agonist
8 or 10 mg/kg, NS effects
MK-801/32/
NMDA antagonist and NA reuptake blocker
0.5, 1, 2 mg/kg, NS effects
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an important role for Otl-NA receptors in enhancing
functional recovery after cortical injury.
Administration of the Otl-NA receptor antagonist,
phenoxybenzamine, in combination with AMPH
blocked the beneficial effect of AMPH/SRE on
recovery after embolic stroke/55/. To investigate
this issue further a variety of Otl-NA agonists and
antagonists were examined for their effects on
recovery of function. The Otl-NA receptor agonists
phenylephrine and methoxamine had no significant
facilitatory effects on recovery of BW ability
following SMCX injury/24,25,29/. In addition, the
Otl-NA antagonist prazosin was administered to
animals after SMCX contusion or ablation. Prazosin
had no detrimental effect in ablated animals but
retarded recovery in animals with contusion (see
Tables 1 and 2). To account for some of the
differences on BW recovery in response to a single
drug dose, a most conservative treatment, it
appeared that recovery in animals with TBI was
more readily disrupted than in animals with ablation
and facilitation of recovery was less readily
produced than after ablation. This may be a result of
the TBI producing selective neuronal death in
subcortical areas in addition to SMCX injury/28/.
The pattern of results provides behavioral
pharmacology data indicating a central role for NA
in recovery after both types of cortical injury. Drugs
which directly or indirectly increased c-NA
activity promoted BW recovery whereas c-NA
receptor antagonists slowed recovery from
hemiplegia. A theoretical problem is that while
selective c-NA antagonists alone slow recovery t
agonists do not facilitate recovery. This issue is
discussed in detail elsewhere/29/. It was concluded
that disruption of the recovery process is less
complicated than its facilitation. While retardation
of recovery can be produced by blocking one
receptor, selective t-NA activation by an agonist
alone is insufficient to "enable" SRE to produce an
enduring enhancement.
As has been reviewed elsewhere/19,31,60/, the
results from preliminary human studies are strikingly
parallel to BW recovery data in non-human animals.
Statistically significant facilitation of recovery from
hemiplegia /16/ and aphasia/67/has been reported
in double blind studies. Obtaining significant results
with 4-5 patients in a group suggests that the
TABLE 2
Drugs tested for effects on recovery of function after
cortical trauma
Catecholamine agonists
Amphetamine/25,64/
Monoamine agonist
2 mg/kg, significant facilitation
Catecholamine antagonists
Haloperidoi/29/
Catecholamine antagonist
0.4 mg/kg, blocks AMPH facilitation and retards recovery
Non-catecholamine agonists
Morphine (unpublished data)
Opiate receptor agonist
5 or 20 mg/kg, NS effects
10 mg/kg, disability specific facilitation
,Specific receptor agonists
Methoxamine/29/
NA1 receptor agonist
1, 4 or 8 mg/kg, NS effects
Prazosin/29/
NA Otl receptor antagonist
4 mg/kg, significant retardation
Yohimbine/4/
NA o2 receptor antagonist
10 mg/kg, disability specific facilitation
Propranolol/29/
NA 131 and 132 receptor antagonist
10 mg/kg, NS effects
Drugs tested for effects on recovery of function in animal
models of stroke*
D-Amphetamine/17,55/
monoamine agonist
embolic stroke model: NS effect with single administration,
significant reduction in morbidity and mortality with
continuous infusion of low dose mg/kg/day, or multiple
doses, 2 mg/kg (effects blocked by phenoxybenzamine)
photochemically-induced focal cortical infarct: significant
enhancement of sensorimotor performance and reversal
of glucose hypometabolism, 4 mg/kg, i.v.
*See /35/ for discussion of ablation/hemiplegia model’s
relevance for functional recovery after stroke.
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AMPH/SRE effect may bc very robust. Also similar
to the observations in laboratory studies is that the
same or similarly acting drugs slow recovery from
herniplcgia aRcr a stroke. A retrospective study/3 I/
compared the recovery rate for two groups of
patients and found that for those given drugs shown
to slow BW recovery after SMCX ablation in rat,
recovery was also slowed after stroke. This
retrospective but double blind study used the same
outcome rncasurc as the AMPH/SRE stroke
studies.
As summarized in Table 3, cq-NA antagonists
dramatically reinstate SMCX symptoms for several
hours in apparently recovered animals at a dose
having no effect on BW in normal animals. The ccI-
NA antagonists, prazosin and phcnoxybcnzarninc,
reinstate BW deficits in both contused and ablated
animals following complete recovery of beam-
walking ability. The reinstatement is unlikely to bc
due to a non-specific drug effect since the deficits
reappear only in the limbs contralateral to the
cortical injury, and do not occur after a sedating
dose of pcntobarbital/24,25/. Taken together these
data indicate that activity at the Ctl-NA receptor is
important for both facilitation and maintenance of
recovery from hcrniplcgia. However, NA is an
important but not a necessary condition since
spontaneous recovery still occurs aRer destruction
of the forebrain NA innervation from the locus
coeruleus/8/. Additionally, increased activity at the
CCl-NA receptor site alone is not sufficient to
produce an enhancement of BW recovery. An
interaction between NA and thg neural activity of
SRE in the cerebellum has been proposed to
account for the MPH/SRE facilitation of recovery
from hcmiplegia /19/. The effect of NA is
considered "enabling or permissive" for the enduring
alterations produced by SRE/19/.
TABLE 3
Drugs tested for reinstatement of symptoms in animals recovered from SMCX injury
Ablation model
Prazosin/61/
NA oc receptor antagonist
2 or 4 mg/kg, significant reinstatement
Phenoxybenzamine/25/
NA cc receptor antagonist
10 mg/kg, significant reinstatement
Cionidine/34,60,61/
NA oc2 receptor agonist
0.1 or 0.4 mg/kg, significant reinstatement, rat and cat
Yohimbine/61/
NA o2 receptor antagonist
0.5, 5 or 10 mg/kg, NS effects
Propranolol/61/
NA I and2 receptor antagonist
20 mg/kg, NS effects
Pentobarbitai/19, p. 121/
Affects many systems
5 mg/kg, for 5 days, NS effects
MK-$01/32/
NMDA antagonist and NA reuptake blocker
0.5 mg/kg, NS effects
Contusion model
Prazosin/29/
NA o receptor antagonist
4 mg/kg, significant reinstatement
Phenoxybenzamine/29/
NA OCl receptor antagonist
10 mg/kg, significant reinstatement
Clonidine/29/
NA oc2 receptor agonist
0.4 mg/kg, significant reinstatement
Propranolol/29/
NA 131 and 12 receptor antagonist
10 mg/kg, NS effects
Haloperidol/29/
Catecholamine antagonist
0.4 mg/kg, significant reinstatement effects only with
chronic administration
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Activity at other NA receptors, which can
indirectly affect activity at c-NA receptors, is also
important in recovery from hemiplegia. The
commonly prescribed antihypertensive clonidine, an
x2-NA agonist which decreases NE release by
activating the NA neurons’ autoreceptors, retards
BW recovery after SMCX ablation in the rat/34/,
but this finding was not replicated in another study
using the identical model/61/. The only important
procedural difference was the use of additional
motivation consisting of occasional "prodding".
Furthermore, the ot-NA antagonists, yohimbine
/4,61/ and idazoxan /35/, which increase NA
release, both facilitateBW recovery after rat SMCX
ablation, similar to AMPH. Like agents that
antagonize cz-NA receptors, drugs which act at
NA receptors can also affect the maintenance of
functional recovery. The c-NA agonist clonidine
reinstates BW deficits following recovery from TBI
or ablation/25,29,61/, an effect that is quite striking
in the recovered cat.
There is a very important clinical relevance of
these data. After patients are admitted to a hospital
for stroke their blood pressure medication is
frequently changed to clonidine. Given its adverse
affects on BW recovery in rat and cat and its
apparent negative effect on recovery from
hemiplegia in stroke patients, clonidine and other
drugs reducing (Zl-NA transmission should not be
administered early after stroke/31/.
INTRACEREBRAL MONOAMINE INFUSION
To further characterize the transmitter(s)
mediating the AMPH/SRE actions on recovery of
function, studies using intraventricular infusions of
the monoamine neurotransmitters with appropriate
SRE were conducted. The results of these studies
showed that the infusion of NA, but not DA or 5-
HT (serotonin), mimicked the effects of the
AMPH/SRE on BW recovery/10 and unpublished
5-HT data of Feeney, Navratil and Boyeson/.
Importantly, Boyeson and Krobert report/13/that a
localized infusion of NE into the cerebellar cortex
contralateral, but not ipsilateral, to the SMCX
injury, facilitates recovery from hemiplegia.
Complimentary reinstatement data have recently
been published/12/. Similarly, microinfusion of the
oq-NA antagonist, phenoxybenzamine, into the
cerebellar cortex contralateral, but not ipsilateral, to
a SMCX ablation reinstates deficits in animals
recovered from SMCX ablation/12/.
In summary, the results of the experiments
reviewed above indicate thatNA plays a critical role
in spontaneous recovery and the AMPH/SRE
enhancement of recovery. Lastly, the integrity of
Ctl-NA receptors is important for recovery of
function alter cortical injury and in maintaining that
recovery.
ENDURING RECOVERY MAINTAINED BY
ADRENAL AUTOGRAFTS
While the short term NA pharmacological
treatment combined with SRE produces an enduring
enhancement of recovery from some symptoms of
cortical injury there may be other serious deficits
remaining. One interesting symptom of unilateral
frontal cortex ablation in the cat is the permanent
and total loss of tactile and proprioceptive placing
reflexes in the contralateral forelimb. As discussed
above, after frontal cortex ablation in the cat tactile
and proprioceptive placing can be temporarily
restored by administration of AMPH, which we
termed a "drug-dependent" functional recovery.
There is some evidence for similar drug-dependent
effects on the very disabling symptom of aphasia
/36/in a chronic stroke patient. In such cases long
term pharmacological treatment may result in
undesirable effects and tolerance. Therefore, we
tested the approach that has been used by others,
transplanting adrenal medulla chromaffin cells into
brain alter frontal ablation/63/ as an endogenous
source of increased NE in the CNS.
Large unilateral frontal motor cortex ablations
were performed in five cats. Reconstruction of the
lesions indicated that they included, in all cats,
removal of the anterior and posterior sigmoid and
coronal gyri and extended into the underlying white
matter without infringing upon the caudate nucleus.
The most ventral aspects of the rostral gyms
proreus and the ventral half of the cingulate gyms
were spared medially. In the two cats that received
"late grafts", there was additional minor damage to
the anterior portions of the anterior ectosylvian and
suprasylvian gyri and the lateral and sylvian gyri.
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These lesions produced a complete loss of tactile
placing and very severe BW deficits. Two time
intervals between cortex ablations and
transplantation were used because work in the rat
demonstrated that a lesion-graft time interval
enhanced graft survival. However, in the cat we
could only guess at the optimal interval. Therefore,
two cats were prepared with a 12 day interval
between ablation and transplant, referred to as
"early" gratis. Two other cats with a 21 day interval
are referred to as "late" gras. One cat had a
unilateral frontal cortex ablation and 21 days later
the right adrenal gland removed but not grafted.
This animal served as a control for some
unanticipated effect of adrenalectomy alone on
recovery from frontal cortex ablation.
For grafting, the animals were reanesthetized
and the cortical wound reexposed. The right adrenal
gland was isolated, its vasculature ligated and the
entire gland removed and placed in sterile, lactated
Ringer’s solution. Under an operating microscope
the medullary tissue was separated from the adrenal
cortex and cut into small pieces (0.5-2.0 mm3). In
the cortical wound, gelfoam was gently retracted
and the field covered with sterile saline-moistened
gauze. The adrenal medullary pieces were picked up
with a glass pipette and one or two pieces placed
into four sites on the floor of the cortical cavity in
the most lateral, medial, rostral and caudal areas of
the ablation.
The survival of the grafts was determined by
processing alternate sections for catecholamine
histochemistry 7-10 months after transplantation.
The data indicated that some chromaffin cells
survived in the grafted wound cavity of all four cats
with transplants. It appeared that the 21 day late
graft interval was much more favorable for survival
of the transplanted chromaffin tissue. In one of the
two early graed animals there were two
catecholamine fluorescing sites. In the other early
graft cat seven fluorescing sites were observed.
However, all but one of these sites were
encompassed by macrophage activity and
encapsulated in scar tissue. The two late grafted
cats had 13 and 24 fluorescent cell clusters which
appeared integrated with the host parenchyma and
had little or no macrophage activity. The ten month
survival of the graft in the late graft animals is
impressive, for the tactile placing data dearly
indicate that the late grafts were physiologically
active in secreting catecholamines.
As illustrated in Figure 1, the effects of late
grafting on restoration of tactile placing was very
dramatic. Only after late grafting were any tactile
placing responses observed in the affected forelimb
of these cats with unilateral frontal ablations.
Following cortical ablation, perfect responding (0
SEMs) was totally abolished contralateral to the
lesion in all animals. After late graining,, tactile
placing was partially (7 of 10 placing responses) and
occasionally completely restored (10 of 10) in both
cats for the 7-10 month duration of the study. In
our experience with many other adult cats with
comparable unilateral lesions, there has been no
spontaneous recovery; this includes an animal which
has been followed for more than seven years. Beam-
walking recovery in late graft animals was also
facilitated, being equivalent to that observed aer
three doses ofAMPH combined with SRE. The late
graft cats had returned to their baseline preablation
BW performance level by 24 days after grafting.
The data from the early graft animals were
inconclusive. The "ablation with adrenalectomy"
control animal showed a recovery rate similar to
that of cats with similar ablations, which returned to
preablation baseline BW scores at 156 days after
graRing. We interpreted the late transplants as
acting similarly to "endogenous minipumps", slowly
releasing catecholamines, and perhaps other
important neurotransmitters, for the 7-10 month
duration ofthe experiment.
This grafting of adrenal chromaffin cells into
cortical wound cavities may be relevant to late
therapy for stroke symptoms. In six carefully
studied aphasia patients, ten treatment sessions at
four-day intervals of AMPH (10-15 mg
administered orally) followed in 30 minutes by one
hour of speech therapy showed an acceleration of
the expected rate of recovery/67/. At three months
poststroke all of these patients obtained measured
recovery from aphasia markedly exceeding their six
month predicted recovery score (based on a
mathematical model and objective aphasia testing).
Additionally, in a double-blind case study, treatment
with 15 mg of orally administered AMPH to a 53
year-old patient with aphasia and hemiplegia 1.5
years after stroke transiently improved several
measures of language, sensory and motor
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performance/36/. However, these improvements in
performance were observed only during the period
of overt drug action. If replicated and extended by
additional research, such cases of drug dependent
symptom alleviation could be amenable to
chromaffin cell autogratts, perhaps even years
following stroke or TBI.
FUNCTIONAL RECOVERY AND ALLEVIATION OF
REMOTE FUNCTIONAL DEPRESSION (DIASCHISIS)
The mechanism(s) of the NA/SRE effect or even
the basis of spontaneous recovery is at present
unclear. There are no detectable effects of
MPH/SRE treatment on the volume ofthe cortical
injury /27/. It has been proposed /19/ that some
symptoms of brain injury result from a remote
functional depression (RFD), a concept formulated
to replace the older theory of diaschisis/19/. The
RFD can be manifest in depressed neuronal
metabolism. It is widely accepted that some types of
selective neuronal death distant from an infarct or
TBI site can be a result of "excitotoxicity"/1/. This
is attributed to a massive release of excitatory
amino acid (EAA) neurotransmitters at the injury
site and/or in distant areas transynaptically mediated
by axons originating from the direct injury/57/. It
was proposed that excessive but sublethal EAA
receptor activation may be the cellular basis of
RFD. According to this soft excitotoxicity
hypothesis /19/, focal cortical injury results in
widespread metabolic depression from the
disruption of ionic homeostasis in neurons injured,
but not killed, by exposure to the massive amounts
ofEAAs.
Atter SMCX ablation or TBI we reported a
reduced local cerebral metabolic rate for glucose
utilization (LCMRGlu), reduced oxidative
metabolism indicated by weaker histochemical stain
intensity for cytochrome oxidase (a mitochondrial
enzyme), and a different pattern oflowered intensity
of histochemical staining for the oxidative enzyme
alpha-glycerophosphate dehydrogenase /19,26/.
Similar to the behavioral recovery data presented
above, the metabolic depression is normalized by
the AMPH/SRE treatment/26/. From that and other
data we hypothesized that enhancement of recovery
results from the alleviation of injury-induced
metabolic depression of structures remote from, but
connected to, the site of injury /19,26/.
Additionally, the administration of haloperidol
worsens the metabolic depression and when
coadministered with AMPH blocks the
normalization of depressed LCMRGlu atter SMCX
injury /26/. Similar effects of AMPH on reduced
glucose metabolism after cortical injury have been
reported in a recent acute 2-DG investigation using
the photochemical infarct model/17/. The authors
report a marked depression ofthe normal pattern of
LCMRGlu activation by vibrissae stimulation at two
weeks-post infarct. During the period of AMPH
action, vibrissae stimulation increased LCMRGIu in
cortical areas not activated in untreated infarcted
animals/17/.
An additional factor that is likely to contribute to
RFD is axotomy of the projections of the locus
coeruleus to the SMCX by ablation or contusion.
The locus coeruleus axonal projections are unusual
in that so few cells give rise to axons which
bifurcate, and the same neuron can send projections
to the ipsilateral SMCX and both cerebellar
hemispheres. Because of this unique anatomy ofNA
forebrain projections, injuring the locus coeruleus
axon terminals in SMCX should influence the
amount of NA released in areas remote from the
injury, such as the cerebellum. To test our
hypothesis, we recently used microdialysis in awake
behaving rats to measure the spontaneous and
AMPH-evoked release of NA in cerebellar cortex
24 hours after SMCX-TBI. Spontaneous NA
release was significantly depressed in the
cerebellum. There was, however, sufficient NA in
stores so that the usual AMPH dose (2 mg/kg i.p.)
increased release by 522-1088%, which slowly
returned to baseline over the 5 hours after injection
/44/. The mechanism proposed as a basis for
enhanced recovery by AMPH/SRE was "...from an
AMPH-evoked increase of norepinephrine within
the cerebellum which, in conjugation with afferent
feedback (SRE) to cerebellar neurons, produces an
enduring use-dependent strengthening of responses
to this input"/19: p.121/. The data from this recent
in vivo cerebellar microdialysis experiment /44/
confirm one important aspect of the theory.
The observed metabolic disturbances remote
from the site of cortical damage, their spontaneous
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Fig. 1: Mean (+SEM) tactile placing responses in cats before and after large unilateral frontal cortex ablations. From post
surgery day 12, the first post grafting test day, to day 152 after early grafting, each point represents the mean group
performance over 4 consecutive test sessions. The results illustrate the perfect performance of all animals prior to
cortical injury and the complete loss of responding in all animals after surgery. Previous work has indicated that this
total loss of responding is permanent. However, as illustrated in the late graft condition, partial restoration of tactile
placing can be produced by transplantation of homologous adrenal medulla cells directly into the cortical wound cavity
21 days following ablations. The adrenalectomy without grafting animal had a unilateral frontal lesion and 21 days later
the right adrenal gland was removed. This was performed to control for the possibility that tactile placing might be
restored by adrenalectomy alone, without the autograft. The data illustrate the enduring amelioration of a presumed
"permanent" deficit after brain damage by grafting an "endogenous catecholamine minipump" into the brain
parenchyma. Analyses of the brain tissue of these animals for catecholamine florescence revealed considerably more
surviving chromaffin cells in animals with late transplants than in the early graft animals at 7-10 months after surgery.
Adapted from Sutton, Hovda and Feeney/63/with permission. In the original publication there were calculation errors
for the last 5 SEMs. With the help of Dr. Sutton, they were recalculated from the raw data. The correct values are
presented in this figure.
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dissipation, and the normalizing effect of AMPH
treatment provide support for the concept of
diaschisis, or remote functional depression. Remote
metabolic disturbances and subsequent
normalization may contribute to observed
behavioral deficits and their spontaneous recovery,
respectively. The effect of AMPH/SRE may be to
accelerate the resumption of normal metabolic and
biochemical processes within neuronal circuits
necessary for recovery of some functions after
cortical injury.
CONCLUSIONS AND IMPLICATIONS FOR
CLINICAL TRIALS
The data reviewed support the proposed central
"enabling" role forNA in spontaneous or treatment-
enhanced functional recovery after cortical injury.
Enhanced functional recovery after cortical injury
by short-term therapy using AMPH, or one of the
many other drugs which increase NA synaptic
activity, is enduring when combined with SRE.
There are several reasons for cautious optimism
regarding the clinical relevance of this laboratory
discovery that AMPH/SRE promotes recovery of
BW in rats with cortical ablation and related
studies. The initiation of treatment can be delayed
for weeks after injury in the cat. The enhancement
of recovery affects several qualitatively different
types of cortical injury and subsequent symptoms of
cortical injury. Importantly, not all deficits following
cortical injury respond to treatment and research is
required to determine those symptoms that do
respond and what drug/SRE protocols are most
effective in promoting recovery.
The enhanced recovery seems more robust in
"higher" species. For example, the effect of
AMPH/SRE on functional recovery is more
dramatic in the cortically injured cat than in rat and
perhaps even more robust in human stroke cases.
There are statistically significant pilot data from two
double blind studies of small samples (N=4 or 5 per
group) of carefully selected stroke cases/16,67/. In
a third double blind study of recovery of stroke
patients from hemiplegia, non-significant differences
were reported comparing a group of 5 patients
given short term AMPH treatment compared to
placebo controls/7/. However, no period of specific
SRE was scheduled following drug or placebo
administration (Dr. S.J. Borucki, personal
communication to DMF). This drug or placebo
treatment was simply incorporated into the
rehabilitation program of the patient. Additionally,
random assignment unfortunately resulted in a
significant difference in the mean age of the two
groups, the average age of the treatment group
being 73 compared to 57 for the control group.
Lastly, for most patients treatment was not initiated
until over a month alter their stroke, which Dr.
Borucki considered a major factor for their negative
findings (personal communication). Nevertheless,
the results of motor function testing between
groups (The Fugl-Meyer test, the same as
successfully used in the earlier studies) showed
striking differences which approach significance.
This study reinforces the hypothesized importance
of SRE scheduled during the period of maximal
drug activity.
Future studies of this treatment approach should
also consider i.m. or s.c. drug administration to
reduce variability of absorption and measurement of
blood drug levels since this could account for some
of the variance between patients and may correlate
with response to treatment. Additionally, when
using small samples, stratified random sampling
should be considered instead of simple random
assignment to match the groups on such important
variables as age. Because such small samples also
usually do not meet the criteria required for
parametric statistical comparisons, non-parametric
statistical analyses may be more appropriate.
Finally, in our laboratory investigations in the rat,
we found that different AMPH dosages are required
depending upon the hemisphere injured/43/. With
the greater cerebral lateralization in human beings,
mixing left and right hemisphere stroke cases in a
group may also increase the variance. With a
sufficient sample size in studies of stroke patients
this factor could be isolated and separately
examined. Clearly, these data generated in different
laboratories warrant continued research to develop
a therapy to promote functional recovery after
cortical damage.
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NOTE ADDED IN PROOF
Studies of precursors for DA or NA, L-DOPA and
L-DOPS respectively, have shown that L-DOPS but not
L-DOPA enhanced recovery of beam walking after
unilateral SMCX ablation in rat (Nishino K, Onyu H,
Masayoshi M. Sensorimotor cortex ablation model.
Functional Neurosurgery 1991; 30: 116-124. The text is
in Japanese but the abstract and figure captions are in
English. Additionally, these authors briefly presented
some of the data in Neuroscience Abstracts, 1991; 17:
150). We have unpublished data also indicating the lack
of any effect on recovery from hemiplegia by L-DOPA.
Their observations warrant replication and extension,
because of the potential usefulness of L-DOPS, which
has weaker cardiovascular side effects than AMPH, but
also promotes recovery after brain damage.
Interestingly, a recent study reported that a single
dose of AMPH, apparently administered without SRE,
significantly slowed beam walk recovery in rats with
photochemical induced infarcts (Bjelk B, Brown A,
Sabouri S, Fuxe K. Beam walking without aversive
stimuli as a tool to record motor recovery alter
photochemical induced unilateral lesions of the sensory-
motor cortex. Training effect contra d-amphetamine
treatment. Neuroscience Abstracts 1993; 19: 1653). The
report ofAMPH slowing motor recovery in this model is
quite surprising since others, using the same stroke
model /17,38/, report AMPH significantly improves
other functional and physiological outcome measures.
For example, Hurwitz et al. /38/ using this
photochemical infarct model and a sensorimotor outcome
measure, note that 4.0 not 2.0 mg/kg ofAMPH, the dose
used in this recent study, significantly enhances recovery.
We have seen a similar requirement for higher or
multiple AMPH doses to enhance recovery in an embolic
stroke model. We await a more detailed publication of
this important experiment because the data conflict with
so many other studies. If replicable and not attributable
to dosage or lack of SRE, the observation may indicate
limitations ofthis therapeutic approach.
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